This Article Full Text Full Text (PDF) All Versions of this Article: 49/6/1196    most recent HYPERTENSIONAHA.106.075085v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reudelhuber, T. L. Articles by Delafontaine, P. Search for Related Content PubMed PubMed Citation Articles by Reudelhuber, T. L. Articles by Delafontaine, P. Related Collections Remodeling ACE/Angiotension receptors Animal models of human disease Hypertrophy

(Hypertension. 2007;49:1196.)
© 2007 American Heart Association, Inc.

Brief Review

Is Angiotensin II a Direct Mediator of Left Ventricular Hypertrophy?

Time for Another Look

From the Laboratory of Molecular Biochemistry of Hypertension (T.L.R.), Clinical Research Institute of Montreal, Montreal, Quebec, Canada; the Department of Pathology and Laboratory Medicine (K.E.B.), Emory University, Atlanta, Ga; and the Department of Medicine (P.D.), Section of Cardiology, Tulane University Health Sciences Center, New Orleans, La.

Correspondence to Timothy L. Reudelhuber, Clinical Research Institute of Montreal, 110 Pine Ave West, Montreal, Quebec H2W 1R7, Canada. E-mail reudelt@ircm.qc.ca

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Hypertensive cardiac remodeling, characterized by left ventricular hypertrophy (LVH) and increased fibrosis, increases the workload of the heart and is a significant risk factor for cardiovascular morbidity and mortality.¹ There is a continuous relationship between left ventricular mass and the likelihood of cardiovascular events, including stroke, heart failure, and coronary artery disease, leading to myocardial infarction (MI).² Virtually all of the clinical trials have demonstrated that antihypertensive treatment achieves some reversal of LVH,³ and reduction of left ventricular mass during antihypertensive treatment has repeatedly emerged as a goal of paramount importance in reducing risk.^4,5 Nevertheless, the interpretation of certain clinical trials has led to the widely held view that inhibition of the renin–angiotensin system (RAS) has favorable effects on cardiac remodeling that go beyond its blood pressure–lowering effects. This view has been supported by the experimental finding that cultured cardiomyocytes hypertrophy in response to exogenously added angiotensin II and has led to the model of the heart as a direct target of the RAS. In the current review, we critically analyze these arguments in light of recent clinical and experimental data with a particular emphasis on genetically modified animals designed to test for the role of a local cardiac RAS in the development of LVH.

	From the Bedside

 
Although an extensive discussion of clinical trials that tested the role of the RAS in cardioprotection is beyond the scope of this review (the reader is referred to recent reviews in References ⁶ and ⁷), the results of most clinical studies suggest that the absolute reduction . . . [Full Text of this Article]

This article has been cited by other articles:

				H. Yue, W. Li, R. Desnoyer, and S. S. Karnik Role of nuclear unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy Cardiovasc Res, September 16, 2009; (2009) cvp285v2. [Abstract] [Full Text] [PDF]

				J. D. Widder, D. Fraccarollo, P. Galuppo, J. M. Hansen, D. P. Jones, G. Ertl, and J. Bauersachs Attenuation of Angiotensin II-Induced Vascular Dysfunction and Hypertension by Overexpression of Thioredoxin 2 Hypertension, August 1, 2009; 54(2): 338 - 344. [Abstract] [Full Text] [PDF]

				J. Cai, F.-F. Yi, L. Yang, D.-F. Shen, Q. Yang, A. Li, A. K. Ghosh, Z.-Y. Bian, L. Yan, Q.-Z. Tang, et al. Targeted Expression of Receptor-Associated Late Transducer Inhibits Maladaptive Hypertrophy via Blocking Epidermal Growth Factor Receptor Signaling Hypertension, March 1, 2009; 53(3): 539 - 548. [Abstract] [Full Text] [PDF]

				K. D. Pendergrass, N. T. Pirro, B. M. Westwood, C. M. Ferrario, K. B. Brosnihan, and M. C. Chappell Sex differences in circulating and renal angiotensins of hypertensive mRen(2).Lewis but not normotensive Lewis rats Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H10 - H20. [Abstract] [Full Text] [PDF]

				P. J. Garabelli, J. G. Modrall, J. M. Penninger, C. M. Ferrario, and M. C. Chappell Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart Exp Physiol, May 1, 2008; 93(5): 613 - 621. [Abstract] [Full Text] [PDF]

				H. D. Xiao, S. Fuchs, E. A. Bernstein, P. Li, D. J. Campbell, and K. E. Bernstein Mice expressing ACE only in the heart show that increased cardiac angiotensin II is not associated with cardiac hypertrophy Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H659 - H667. [Abstract] [Full Text] [PDF]

				J. Xu, O. A. Carretero, C.-X. Lin, M. A. Cavasin, E. G. Shesely, J. J. Yang, T. L. Reudelhuber, and X.-P. Yang Role of cardiac overexpression of ANG II in the regulation of cardiac function and remodeling postmyocardial infarction Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1900 - H1907. [Abstract] [Full Text] [PDF]